Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Cormorant Asset Management, LP | 10% Owner | Sep 20 '24 | Buy | 20.01 | 350,000 | 7,003,761 | 2,375,000 | Sep 24 04:04 PM | | CATLIN AVERY W | Director | Sep 04 '24 | Proposed Sale | 56.43 | 888 | 50,109 | | Sep 04 04:44 PM | | Moran Sean F. | Chief Financial Officer | Jun 17 '24 | Option Exercise | 14.10 | 6,730 | 94,893 | 55,335 | Jun 18 05:59 PM | | Moran Sean F. | Chief Financial Officer | Jun 14 '24 | Option Exercise | 8.57 | 9,355 | 80,187 | 56,393 | Jun 18 05:59 PM | | Moran Sean F. | Chief Financial Officer | Jun 18 '24 | Option Exercise | 30.00 | 1,958 | 58,740 | 50,563 | Jun 18 05:59 PM | | Moran Sean F. | Chief Financial Officer | Jun 14 '24 | Sale | 49.87 | 9,355 | 466,569 | 48,605 | Jun 18 05:59 PM | | Moran Sean F. | Chief Financial Officer | Jun 17 '24 | Sale | 46.77 | 6,730 | 314,789 | 48,605 | Jun 18 05:59 PM | | Moran Sean F. | Chief Financial Officer | Jun 18 '24 | Sale | 42.12 | 1,958 | 82,479 | 48,605 | Jun 18 05:59 PM | | Cohen Yuval | Chief Executive Officer | Jun 18 '24 | Option Exercise | 24.42 | 15,759 | 384,859 | 96,067 | Jun 18 05:58 PM | | Cohen Yuval | Chief Executive Officer | Jun 14 '24 | Option Exercise | 9.91 | 29,317 | 290,498 | 101,230 | Jun 18 05:58 PM | | Cohen Yuval | Chief Executive Officer | Jun 17 '24 | Option Exercise | 25.90 | 11,103 | 287,530 | 93,733 | Jun 18 05:58 PM | | Cohen Yuval | Chief Executive Officer | Jun 14 '24 | Sale | 50.17 | 29,317 | 1,470,722 | 84,400 | Jun 18 05:58 PM | | Cohen Yuval | Chief Executive Officer | Jun 18 '24 | Sale | 42.24 | 22,938 | 968,832 | 77,221 | Jun 18 05:58 PM | | Cohen Yuval | Chief Executive Officer | Jun 17 '24 | Sale | 46.02 | 11,103 | 510,963 | 84,400 | Jun 18 05:58 PM | | HOLMER ALAN F | Director | Jun 14 '24 | Option Exercise | 30.00 | 1,667 | 50,010 | 5,829 | Jun 14 04:24 PM | | Moran Sean F. | Chief Financial Officer | Apr 10 '24 | Option Exercise | 30.00 | 1,787 | 53,610 | 48,605 | Apr 11 09:17 AM | | Cormorant Asset Management, LP | 10% Owner | Mar 08 '24 | Buy | 44.38 | 300,000 | 13,314,193 | 2,025,000 | Mar 11 05:34 PM | | Cormorant Asset Management, LP | 10% Owner | Mar 07 '24 | Buy | 40.05 | 250,000 | 10,013,367 | 1,725,000 | Mar 11 05:34 PM | | Cormorant Asset Management, LP | 10% Owner | Feb 02 '24 | Buy | 19.00 | 750,000 | 14,250,000 | 1,475,000 | Feb 06 04:00 PM | | HOLMER ALAN F | Director | Jan 26 '24 | Option Exercise | 4.97 | 629 | 3,126 | 1,379 | Jan 30 06:07 PM | | Cohen Yuval | Chief Executive Officer | Jan 26 '24 | Option Exercise | 4.97 | 7,179 | 35,680 | 7,179 | Jan 30 04:56 PM | | Cormorant Asset Management, LP | 10% Owner | Jan 26 '24 | Buy | 32.24 | 282,632 | 9,111,941 | 725,000 | Jan 30 04:23 PM |
|
